E
EyePoint Pharmaceuticals D
D
EYPT
14.330
USD
-0.20
(-1.38%)
مغلق
حجم التداول
21,004
الربح لكل سهم
-3
العائد الربحي
-
P/E
-5
حجم السوق
1,195,579,844
المقالات
العنوان: EyePoint Inc.
القطاع: Healthcare
الصناعة: Biotechnology
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.